Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS). It has a longer half-life compared to other benzodiazepines.
## Primary Indications
Adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initiation:** Typically 5 mg twice daily.
* **Titration:** May be increased by 5-10 mg every 7 days.
* **Maintenance:** Target dose is usually 10-20 mg twice daily.
* **Maximum:** Do not exceed 40 mg per day.
## Pediatric Dosing (2 to less than 10 years of age)
* **Initiation:** Typically 2.5 mg twice daily.
* **Titration:** May be increased by 2.5-5 mg every 7 days.
* **Maintenance:** Target dose is usually 5 mg twice daily.
* **Maximum:** Do not exceed 10 mg per day.
## Pediatric Dosing (10 to less than 18 years of age)
* **Initiation:** Typically 5 mg twice daily.
* **Titration:** May be increased by 5-10 mg every 7 days.
* **Maintenance:** Target dose is usually 10 mg twice daily.
* **Maximum:** Do not exceed 20 mg per day.
*Note: Dosing may vary based on individual response and tolerability. It is often initiated at a lower dose and titrated slowly.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution and consider a reduced dose. Data is limited.
* **Renal Impairment:** Use with caution. Data is limited.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, fatigue, aggression, irritability, affect lability, gait disturbance.
* **Serious:** Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), withdrawal symptoms, suicidal behavior and ideation, respiratory depression, dependence and abuse potential.
## Key Drug Interactions
* **CNS Depressants:** Increased risk of sedation and respiratory depression (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines, antipsychotics).
* **CYP3A4 Inhibitors/Inducers:** May affect clobazam levels.
* **Other Anticonvulsants:** Monitor for additive effects and potential changes in efficacy or toxicity. Clobazam is a CYP2C19 inhibitor and may increase levels of certain anticonvulsants (e.g., phenytoin, phenobarbital).
## Monitoring
* Seizure frequency and type.
* Signs of somnolence, sedation, and central nervous system depression.
* Signs of withdrawal symptoms upon discontinuation.
* Behavioral changes, including suicidal ideation and behavior.
* Skin reactions.
* Concomitant medication levels if clinically indicated.
## Clinical Pearls
* Withdrawal symptoms can occur upon abrupt discontinuation and may be severe. Taper dose gradually.
* Clobazam is associated with a higher risk of serious skin reactions compared to some other benzodiazepines. Patients should be advised of the signs and symptoms.
* Risk of dependence and abuse exists. Use for the shortest duration necessary.
* Use caution when co-administering with other CNS depressants.
***
*This information is intended for healthcare professionals. It is essential to consult the official prescribing information and relevant clinical guidelines for complete details and to ensure patient safety. Dosing and management may vary based on patient-specific factors and local protocols.*
